WeightWatchers Partners with Amazon for Effortless Medication Delivery

WeightWatchers partners with Amazon to ease delivery of weight-loss medications, boosting its shares by 9% and benefiting from easy prescription services. Additionally, the FDA approved a new eye therapy from Glaukos Corp, promising less painful treatment options for a serious vision condition, raising their shares by 2.6%.

In a strategic move, WeightWatchers has teamed up with Amazon to streamline the delivery of weight-loss drugs for its members. The integration includes providing injectable GLP-1 obesity treatments, enhancing the efficiency of receiving prescriptions through Amazon Pharmacy, and boosting WeightWatchers' shares by 9%.

WeightWatchers' Chief Operating Officer Jon Volkmann highlighted how this partnership allows customers to verify medication availability and access seamless refrigerated drug delivery, effectively leveraging Amazon's robust distribution system.

Meanwhile, in pharmaceutical developments, the U.S. FDA has approved a new eye therapy from Glaukos Corp, aiming to offer a less painful solution for treating a progressive eye condition. This announcement positively affected Glaukos' stock, which rose by 2.6% in premarket trades.

(With inputs from agencies.)